HHV8 and EBV‐negative primary effusion‐based lymphoma: A case report of a new provisional entity and review of literature

Marta Canelo‐Vilaseca(Universitat Autònoma de Barcelona), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Isabel Granada(Josep Carreras Leukaemia Research Institute), Ana F. Castillo(Consejo Nacional de Investigaciones Científicas y Técnicas), Javier Grau, Gustavo Tapia(Hospital Universitari Germans Trias i Pujol), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Josep‐María Ribera(Universitat Autònoma de Barcelona), A. Palomar Muñoz(Institut d'Investigació Biomédica de Bellvitge), Marc Sorigué(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Alba Mesa(Universitat Autònoma de Barcelona), Elisa Orna(Universitat Autònoma de Barcelona)
Clinical Case Reports
May 1, 2023
10.1002/ccr3.7282
Cited by 1

Related Papers

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|457
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
|Blood|2016|329
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
|Journal of Clinical Oncology|2008|282
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
|Haematologica|2011|215